The eye, like most organs, has an intricate plumbing system. Pressure builds when drainage is impaired, and this condition—glaucoma—can cause irreversible vision loss. Certain popular anti-inflammatory eye medications that contain steroids can in some cases compound the problem, although scientists have been at a loss to understand why.
PocDoc, a leading UK digital health diagnostics company, has launched what it says is the world’s first smartphone-based test for type 2 diabetes risk including the gold-standard blood biomarker, HbA1c, a landmark step in diabetes prevention according to the company.
An AI tool could help cardiologists identify and target cells that trigger arrhythmia in patients with ventricular tachycardia, a serious heart condition.
Researchers at National Taiwan University developed a biodegradable, electroconductive self-healing hydrogel combined with acupuncture that restores motor function and protects brain neurons in Parkinson’s disease models.
Researchers at Baylor College of Medicine have developed an artificial intelligence (AI) model that reveals how protein modifications link genetic mutations to disease. The method, called DeepMVP and published in Nature Methods, significantly outperforms previously published models and has implications for the development of novel therapeutics.
Researchers have developed a new light technology that appears to improve cognitive function in Alzheimer’s patients in clinical trials. The hope is that the idea can be developed into ordinary lamps that people can install to prevent the disease.
Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their highly effective vaccines to fight the virus.
Within the next few years, doctors may be able to spot signs of Alzheimer’s disease and other dementias using routine eye exams well before symptoms appear, a new study suggests.
Scientists at the Icahn School of Medicine at Mount Sinai have developed a powerful new computational tool that could transform how cancer tissues are analyzed and help pave the way for more personalized treatments.
Researchers at the University of Chicago have developed a “universal” chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing barriers in cancer immunotherapy. Promising initial testing results, published in Science Advances, suggest that this new form of CAR-T cell therapy could dramatically change the treatment landscape for certain cancers.